Advanced cancer patients experience stress and are at risk for developing psychological problems. Early diagnosis and suitable intervention are very important for their quality of life and compliance with chemotherapy. The Hospital Anxiety and Depression Scale (HADS) is one of the most commonly used mood scales; however, HADS has not been validated for use with cancer patients undergoing chemotherapy. The purpose of this study was to validate HADS as a screening tool for psychological distress among cancer patients undergoing chemotherapy. We also identified possible factors contributing to psychological distress and explored the development of original screening tools. Fifty subjects agreed to complete HADS and consult with psychiatric specialists. Possible contributing factors to psychological distress were identified by HADS and logistic regression analysis. The mean score for patients with psychological distress was 20.0 ± 8.93, and for patients without distress was 9.67 ± 6.11; scores for patients with psychological distress were significantly higher. The optimal cutoff point of psychological distress appeared to be 17. This cutoff point was associated with 72.7% sensitivity and 82.1% specificity. The factor "recurrent cancer" (p=0.043) had an odds ratio of 7.24 (1.21-61.2). We verified that HADS is a useful screening tool for cancer patients undergoing chemotherapy. The factor "recurrent cancer" was shown to contribute to psychological distress. Palliat Care Res 2011; 6(2): 150-157
Introduction
Patients with advanced or recurrent cancer experience many stressful events, including the initial shock of cancer diagnosis, prognosis, chemotherapy, adverse events of treatment, and loss of physical strength due to disease progression 1) . This stress in turn increases the risk of developing psychological distress due to depression or adjustment disorder. In fact, 47% of cancer patients suffer from depression or they develop an adjustment disorder 2) .
Most patients with advanced or recurrent cancer receive chemotherapy for both a survival benefit and better quality of life. Onset of psychological distress often causes not only a reduction of quality of life but also an interruption of treatment for cancer patients undergoing chemotherapy 3, 4) . Therefore, early identification and diagnosis of psychological distress and suitable intervention are extremely important when administering chemotherapy to patients with advanced or recurring cancer. Nevertheless, it is often difficult for medical staff who have no training or expertise in psychological disorders to properly diagnosis psychological distress 5, 6) . As the number of cancer patients is increasing, it is necessary to work with psycho-oncologists to develop useful screening tools that can be used to diagnosis psychological distress.
The Hospital Anxiety and Depression Scale (HADS) is one of the most commonly used mood scales 7) . HADS is a self-assessment scale consisting of 14 items divided into areas of anxiety and depression. The subject responds using a four-point scale. A number of studies have suggested that HADS reliably measures anxiety and depression in cancer patients 8, 9) and should be adopted as a routine clinical tool for screening for psychological distress 10) . In Japan, were excluded because we believed that participation in the study was an additional and excessive burden.
Assessment of psychological distress
A psychiatric specialist from the Kyushu University Hospital privately interviewed each subject and used the Structured Clinical
Interview from the Diagnostic and Statistical Manual of Mental
Disorders, 4th edition revised (DSM-ⅣR) to assess whether the patient met the criteria for psychological distress. The interviewer was blind to the results of HADS.
HADS
HADS is a 14-item self-assessment scale for measuring anxiety and depression. On admission, eligible patients received an explanation of the study from their physician. If they consented to participate, subjects completed HADS and then had a consultation with a psychiatric specialist. HADS was assessed using the total score as in the previous study conducted by Kugaya et al. 11) . Patients who completed HADS and had a psychiatric consult within the past 6 months were excluded from the study. Those patients were excluded because the HADS assessment of changes over time is not defined well and so we assessed HADS in conjunction with the psychiatric consult.
4 Social, physical, and disease data Social, physical, and disease data were obtained from medical records of oncologists, psychiatric specialists and oncology nurses. of patients had pain, family support, counseling, a shared hospital room, and a family history of cancer.
Prevalence of psychological disorders
Twenty-two (44%) of 50 patients were diagnosed with a psychological disorder (Fig. 1) ; 13 had adjustment disorder (anxiety), 8 had adjustment disorder (mixed type), and 1 had major depression.
HADS in cancer patients undergoing chemotherapy
The mean score of HADS was 14.3 ± 9.07, with a range of 0 to 36 points. The mean score for the 22 patients with psychological distress was 20.0 ± 8.93, and for the 28 patients without distress was 9.67 ± 6.11.
HADS scores for patients with psychological distress were significantly higher than those without psychological distress (p<0.0001, Fig. 2 ).
ROC curve and cutoff by HADS
In the ROC curve (Fig. 3, Table 2 ), the optimal cutoff point for the screening of psychological distress was considered to be 17 points, with a sensitivity of 72.7% (95% confidence interval〔CI〕 :
0.58-0.85) and a specificity of 82.1% (95% CI: 0.68-0.91).
Factors that were useful in screening for psychological distress in combination with HADS were identified by logistic regression analysis. The factor "recurrent cancer" made a signif icant contribution in the diagnosis of psychological distress (p=0.043; odds ratio〔OR〕 , 7.24; 95% CI, 1.21-61.2). The predictive probability of HADS for the diagnosis of psychological distress was evaluated; the probability for the recurrent group was significantly higher than that for the primary group. The predictive probability at the cutoff of 17 was 0.866 for the recurrent group and 0.472 for the primary group (Fig. 4) .
Discussion
We investigated the validity of HADS as a screening tool 
Gall bludder 1 The mean score of HADS was 14.3 ± 9.07, with a range of 0 to 36 points. The mean score for the 22 patients with psychological disorder was 20.0 ± 8.93, and for the 28 patients without distress was 9.67 ± 6.11. Intergroup comparisons were performed using the Student's t-test.
Fig. 1 Prevalence of psychological disorders
A psychiatric specialist in the Kyushu University Hospital privately interviewed each subject (n=50) and used the Structured Clinical Interview from the DSM-IVR to assess whether the patients met the criteria for psychological distress.
for psychological distress among cancer patients undergoing chemotherapy. Forty-four percent of patients had some degree of psychological distress. The prevalence of psychological distress among the subjects in the present study was similar to the frequency observed in terminally ill cancer patients in previous studies 2, 14, 15) . Therefore, we recommend initiation of intervention for psychological symptoms for cancer patients undergoing chemotherapy.
As HADS scores for patients with psychological distress were significantly higher than those for patients without distress, we concluded that HADS is a useful screening tool for cancer patients undergoing chemotherapy.
In this study, the optimal cutoff score was 17, which showed a higher trend than that of the previous study by Kugaya et al. 11) . In another study of head and neck cancers, the optimal cutoff score was 15 16) . Therefore, the optimal cutoff may be susceptible to clinical settings. We hypothesize that most patients with advanced or recurrent cancer who receive chemotherapy will experience stress and anxiety related to disease progression and recurrence. Also the chemotherapy itself causes adverse physical events and additional psychological distress. The false-negative rate for our cutoff score (26.3%) was equivalent to the previous study 16) .
In the present study, pain, family support, and a shared hospital room were not significantly associated with HADS. These findings differ from those of a previous report in which these factors were found to be associated with psychological distress 17) . Because HADS is a self-assessment scale, we need to investigate the timing of completion of HADS and the variability of scores during cancer treatment.
Six patients (12%) with psychological distress were diagnosed using HADS with a cutoff of 17, and false-positive results were obtained for five patients (10%). To increase the precision of HADS as a screening method, we investigated possible factors contributing to psychological distress by combining HADS with logistic regression analysis. We identified one significant factor, "recurrent cancer". Two of six patients (33%) who had recurrent cancer with HADS < 17 were accurately diagnosed with psychological distress, and all five patients who had recurrent cancer with HADS > 17
were diagnosed with psychological distress. These results indicated that the factor of recurrent cancer significantly contributed to psychological distress as identified by HADS.
Our study has some limitations. Our sample was small and limited to hospitalized patients; therefore, the sample may not be representative of all cancer patients. Also we did not consider testretest reliability of HADS in this study. Some patient selection bias could exist and factors such as pain, constipation, and fatigue were not measured by objective scales. We are planning a large prospective cohort study to verify the validation of HADS in combination with other diagnostic factors, including pain, family support, and recurrent cancer.
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The cutoff point was chosen to minimize the sum of 1-specificity (false-positive) and false-negative rate. Fig. 4 Factors involved in the diagnosis of psychological disorders The predictive probability of HADS for the diagnosis of psychological disorders was plotted for each value of HADS. The predictive probability at the cutoff of 17 was described for the each group.
Fig. 3 ROC curve
The sensitivity and 1-specificity of screening for psychological distress were plotted for each value of HADS. 
化学療法中の進行がん患者における精神症状発現の スクリーニング法としての HADS の有用性

